Each 1g Elocon®-M cream contains: 

• Mometasone furoate     0.1% w/w
• Miconazole nitrate 2% w/w in a suitable cream base.

• Elocon®-M cream is a combination of medium potency corticosteroid Mometasone furoate and Miconazole nitrate. Elocon®-M cream is indicated for skin infections caused by Candida spp. or dermatophytes in which inflammatory and pruritic manifestations are prominent.

• Elocon®-M cream is contraindicated in patients who are hypersensitive to Mometasone furoate, to Miconazole nitrate or to any ingredient in this preparation.

• since safe use of Mometasone furoate in pregnant women has not been established, topical corticosteroids should be used during pregnancy, only if the potential benefit justifies the potential risk to the fetus.
• It is not known whether topical administrations of cor-ticosteroids could result insufficient systemic absorp-tion to produce detectable quantities in the breast milk, thus a decision should be made, whether to dis-continue nursing or to discontinue the drug taking into account the importance of the drug to the mother.

• Local adverse reactions reported very rarely with Elocon®-M, include burning, pruritus, stinging and signs of skin atrophy. 

• Apply a thin film of Elocon®-M cream to the affected skin areas once or twice daily.

• Systemic absorption of topical corticosteroid will be increased, if extensive technique is used. Suitable precautions should be taken under these conditions or when longterm use is anticipated, particularly in infants and children.
• Use of topical corticosteroid in children should be limited to the least amount compatible with an effec-tive therapeutic regimen.
• If irritation or sensitizations develops with use of Elocon®-M cream, treatment should be discontinued.
• Excessive or prolonged use of topical corticosteroids can suppress HPA axis resulting in secondary adrenal insufficiency.

• Elocon®-M Cream: aluminum tube 20 g.

• Store at a temperature below 25 °C.